Kenvue Inc. (NYSE: KVUE) is a prominent player in the consumer health industry, known for its wide range of health and wellness products. The company operates in a competitive market, with rivals like Procter & Gamble and Johnson & Johnson. On January 29, 2026, Jefferies set a price target of $18 for KVUE, while the stock was trading at $17.20, indicating a potential upside of about 4.65%.
Despite this optimistic target from Jefferies, KVUE has received a consensus "Hold" rating from eighteen brokerages, as reported by Marketbeat. Among these, twelve analysts recommend holding the stock, while five suggest buying, and one strongly recommends buying. The average 1-year target price from these analysts is $20.23, suggesting a more bullish outlook compared to Jefferies' target.
Recent analyst reports show mixed sentiments. Johnson Rice maintained a "neutral" rating, while Citigroup lowered its price target from $20.00 to $17.00, keeping a "neutral" stance. Canaccord Genuity Group also reaffirmed a "hold" rating, significantly reducing its price objective from $26.00 to $15.00. These varied opinions reflect the uncertainty surrounding KVUE's future performance.
Currently, KVUE's stock price on the NYSE is $17.20, a slight decrease of 0.81% or $0.14. The stock has experienced fluctuations today, ranging from a low of $17.18 to a high of $17.44. Over the past year, KVUE has seen a high of $25.17 and a low of $14.02, indicating significant volatility in its stock price.
Kenvue's market capitalization is approximately $32.96 billion, with a trading volume of 42.63 million shares. This substantial market cap and trading volume highlight the company's strong presence in the market, despite the mixed analyst ratings and recent price fluctuations.
